問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Koo Foundation Sun Yat-Sen Cancer Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 112Taipei CityBeitou

Recruiting Trial

113Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

203Cases

2021-05-03 - 2034-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2020-10-15 - 2026-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-04-01 - 2029-09-01

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

  • Condition/Disease

    Follicular Lymphoma

  • Test Drug

    懸液用粉劑

Participate Sites
9Sites

Recruiting9Sites

2024-12-26 - 2028-10-20

Phase III

Active
A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib versus Investigator’s Choice in Adult Patients with Relapsed/Refractory Peripheral T-cell Lymphoma

  • Condition/Disease

    Relapsed/Refractory Peripheral T-cell Lymphoma

  • Test Drug

    injective

Participate Sites
8Sites

Recruiting8Sites

2020-10-15 - 2027-09-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2017-09-01 - 2023-04-20

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-05-18 - 2023-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2025-05-01 - 2029-03-06

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-07-01 - 2023-05-31

Phase II

Completed
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments

  • Condition/Disease

    Advanced Breast Cancer

  • Test Drug

    BYL719

Participate Sites
3Sites

Terminated3Sites

2025-04-04 - 2029-12-07

Phase I/II

Not yet recruiting
A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    LUTATHERA® (AAA601) NETSPOT® (AAA501)

Participate Sites
3Sites

Recruiting3Sites

1 8 9 10 11 12 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB